Glaucoma,the major cause of global irreversible blindness,is a chronic neurodegenerative disease of the optic nerve.Apoptosis of retinal ganglion cells (RGCs) and progressive loss of optic nerve axons results in structural and functional deficits in glaucoma patients.Growing evidence obtained from clinical and experimental studies over the last decade strongly suggests the involvement of the immune system in the neurodegenerative process of glaucoma.This review aims to provide a perspective on the complex interplay of cellular events during glaucomatous neurodegeneration that involves aberrances or dysfunctions of immune system,such as ocular immune privilege,glial activation response,T cell-mediated immune responses,autoantibody-mediated immune responses,complement fixation reaction and aging,oxidative stress.The complex interplay of cellular events amplify the primary injury process and contribute to disease progression by oxidative stress and immune response,ultimately lead to cell death with loss of RGCs.

Objective: Our purpose was to study the predictive factors of interferon(IFN) therapeutic effectiveness. Methods:Genotypes of HCV, HCV RNA quantities, β2 microglobulin, 2′- 5′oligoadenylate synthetase, and peripheral blood lymohocyte subgroup were detected by using specific primer PCR assay, energy transference technique of signal primer, sheet chromatography, radioimmunoassay, and APAAP immunoenzyme bridge technique respectively in 20 blood samples of patients with chronic hepatitis C. Results:(1)The patients who had lower level of HCV RNA before treatment and had continuing decreased HCV RNA level after treatment had good response to IFN treatment in follow-up survey. (2)The patients with HCV-Ⅲ type had complete response much more than those with HCV-Ⅱ type (P＜0.05).(3)The patients with lower level of 2′- 5′oligoadenylate synthetase before treatment might have good response to IFN treatment. (4) There was no significant change in β2 microglobulin level before and after treatment and in different response groups before treatment.(5) The CD+3, CD+4, and CD+4/CD+8 in peripheral blood increased after treatment. The patients in complete response group had higher level CD+3, CD+4, and CD+4/CD+8 than those in part response and non-response groups, but there was no significance in statisitcs. Conclusion:The HCV RNA quantities, HCV genotypes, 2′- 5′oligoadenylate synthetase level before treatment were predictive factors of IFN therapeutic effectiveness. The changes of HCV RNA level in treatment and follow-up survey had important significance in therapeutic evaluation, β2 microglobulin level, and lymphocyte subgroup before treatment were not used as predictive factors for IFN therapeutic effectiveness.

Objective To observe the application of angiotensin Ⅱ receptor antagonist valsartan in reducing minim albuminuria in earlier period of the diabetes and kidney disease.Methotis 36 patients Who administered angiotenain Ⅱ receptor antagonist valsartan 80～160nag,qd,for 8 weeks.Compared with symptoms before the treatment,the blood pressure,the amount of the urinary albuminufia,and observed the change of the empty stomach blood sugar,the saccharified hemoglobin,the triglyceride,the total cholesterol,the endogenous creatinine clearance rate,etc.Results After the treatment,the urinary albumin drops obviously(P＜0.01),While the blood pressure,the empty stomach blood sugar,the saccharified hemoglobin,the triglyceride,the total cholesterol and the endogenous creatinine clearance rate have no obvious change.There is no obvious side effect during therapeutic process.Conclusion The application of angiotenain Ⅱ receptor antagonist valsartan can reduce the amount of the urinary albumin,is the effective way in treating the earlier period of the diabetes and kidney disease.

ATP Binding Cassette Transporter, Sub-Family B ; metabolism ; Animals ; Anticonvulsants ; pharmacology ; Brain ; drug effects ; metabolism ; Rats

ATP-Binding Cassette, Sub-Family B, Member 1 ; biosynthesis ; Animals ; Brain ; metabolism ; Disease Models, Animal ; Glycoproteins ; metabolism ; Male ; Rats ; Rats, Sprague-Dawley ; Status Epilepticus ; metabolism

Bone Marrow Examination ; Chediak-Higashi Syndrome ; complications ; diagnosis ; pathology ; Cough ; etiology ; Diagnosis, Differential ; Fatal Outcome ; Female ; Fever ; etiology ; Humans ; Infant ; Leukocytes ; pathology

Child ; Chromobacterium ; Female ; Humans ; Sepsis ; drug therapy ; etiology ; microbiology ; mortality

Objective To analyze and compare the incidence of diarrhea between cerebral hemorrhage and infarction. Method We observed and compared the time when diarrhea occurred in both 147 cases of cerebral hemorrhage patients and 142 cases of cerebral infarction patients by using statistical methods. Result The incidence of diarrhea in former group was 36.05%, and that of latter was 16.91%. Conclusions The incidence in patients with diarrhea of cerebral hemorrhage was markedly higher than that of patients with cerebral infarction. This may attribute to the higher intracranial pressure in cerebral hemorrhage patients than that of cerebral infarction ones. The complications of reduction of immune function,intestinal infection and hypoproteinemia may be the other factors resulting in the higher incidence of diarrhea in cerebral hemorrhage patients than that of cerebral infarction ones.

Objective To study the valid correct method for reagent selection, calibration of analyzers, and internal quality control protocol. Methods Reagents were selected by comparing with BRENGER Mannheim(BM)reagent used in Hitachi 7170A. Analyzers were calibrated once a week. One internal quality control chart was set up for three analyzers. Specimens were analyzed by the three machines respectively. Results Except for amylase, all the results obtained from the three analyzers were not significant. Conclusion The recommended quality control protocol is useful to obtain comparable results from different automatic biochemistry analyzers.

Objective To explore therapeutic efficacy of endoscopic biliary stent placement in the management of bile leakage following hepatobiliary surgery.Methods 11 cases of bile leakage following hepatobiliary surgery were reviewed retrospectively from January 2001 to December 2005.New clinical classifications of bile leakage were proposed: type I,leakage from cystic duct;type II,leakage from extrahepatic bile duct(diameter of leakage less than 1/3 diameter of biliary duct was type IIA;more than 1/3 was type IIB);type III,leakage from intrahepatic bile duct(leakage from intrahepatic bile duct cecum was type IIIA;leakage from intrahepatic bile duct under draining hepatic segments was type IIIB;above draining hepatic segments was type IIIC);type IV,leakage from Luschka duct.Results In 11 cases,there were 6 cases of type I,2 cases of type IIA,1 case of type IIIA,and 2 cases of type IIIB.4 cases were placed only stents,and Oddi sphincterotomy combined with stent placement were performed in 7 cases.Stents were taken out at 3 weeks(6 cases),1 month(2 cases),2 weeks(1 case),6 months(1 case) and 9 months(1 case) postoperatively.Abdominal pain was relieved in 11 cases after endoscopic treatment,with disappearance of biliary drainage from abdominal cavity and subsidence of jaundice.1 case was followed up for 6 months,and other 10 cases were followed up for 1-3 years,with no recurrence of abdominal pain,fever,jaundice and seroperitoneum,and hemobilirubin became normal.Conclusions Endoscopic biliary stent placement is one of effective therapeutic procedures in the management of most bile leakage following hepatobiliary surgery.New classification of bile leakage may be taken as a guide to select therapeutic procedures.